Moleculent Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $20M

  • Investors
  • 5

Moleculent General Information

Description

Operator of a biotechnology company intended to decode human biology with advancements in life science. The company develops technology-enabled products that leverage new insights into the molecular foundation of human biology, enabling healthcare professionals to avail molecular science-based therapies and diagnostics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Scheeles Väg 1
  • 171 65 Solna
  • Sweden
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Scheeles Väg 1
  • 171 65 Solna
  • Sweden

Moleculent Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Moleculent Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 30-Apr-2026 $20M Completed Generating Revenue
2. Early Stage VC (Series A) 11-Jun-2024 Completed Generating Revenue
1. Early Stage VC 31-Dec-2022 $10.2M $10.2M Completed Startup
To view Moleculent’s complete valuation and funding history, request access »

Moleculent Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view Moleculent’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Moleculent Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to decode human biology with advancements in life science. The company deve
Discovery Tools (Healthcare)
Solna, Sweden
50 As of 2026

Cambridge, United Kingdom
 

South Plainfield, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Moleculent Competitors (29)

One of Moleculent’s 29 competitors is Abcam, a Corporate Backed or Acquired company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abcam Corporate Backed or Acquired Cambridge, United Kingdom
Genewiz Formerly VC-backed South Plainfield, NJ
Novus Biologicals Formerly PE-Backed Centennial, CO
CIS Bio International Formerly PE-Backed Saclay, France
Source Bioscience Corporation Nottingham, United Kingdom
You’re viewing 5 of 29 competitors. Get the full list »

Moleculent Patents

Moleculent Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025133768-A1 Transfer of reporter probes from a biological sample to a support by direct contact Inactive 21-Dec-2023
EP-4623102-A1 Heat-based transfer of reaction products made in situ to a planar support Pending 28-Dec-2022
US-20260209832-A1 Heat-based transfer of reaction products made in situ to a planar support Pending 28-Dec-2022
WO-2024141901-A1 Heat-based transfer of reaction products made in situ to a planar support Inactive 28-Dec-2022
AU-2023213160-A1 Detection of proximity assay products in situ Pending 26-Jan-2022 C12Q1/6841
To view Moleculent’s complete patent history, request access »

Moleculent Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Moleculent Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Rubicon Healthcare Partners Growth/Expansion Minority
ARCH Venture Partners Venture Capital Minority
Eir Ventures Venture Capital Minority
Subvenio Invest Venture Capital Minority
Syntrans Family Office Minority
To view Moleculent’s complete investors history, request access »

Moleculent FAQs

  • When was Moleculent founded?

    Moleculent was founded in 2021.

  • Where is Moleculent headquartered?

    Moleculent is headquartered in Solna, Sweden.

  • What is the size of Moleculent?

    Moleculent has 50 total employees.

  • What industry is Moleculent in?

    Moleculent’s primary industry is Discovery Tools (Healthcare).

  • Is Moleculent a private or public company?

    Moleculent is a Private company.

  • What is Moleculent’s current revenue?

    The current revenue for Moleculent is .

  • How much funding has Moleculent raised over time?

    Moleculent has raised $57.4M.

  • Who are Moleculent’s investors?

    Rubicon Healthcare Partners, ARCH Venture Partners, Eir Ventures, Subvenio Invest, and Syntrans have invested in Moleculent.

  • Who are Moleculent’s competitors?

    Abcam, Genewiz, Novus Biologicals, CIS Bio International, and Source Bioscience are some of the 29 competitors of Moleculent.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process